

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (Canceled)

22. (Previously Presented) A process for producing a cloned macrophage activating factor (GcMAFc) comprising:

- (a) cloning a Gc1 isoform into a baculovirus vector;
- (b) expressing the cloned Gc1 isoform, thereby producing a cloned Gc1 protein, wherein the Gc1 protein comprises approximately 458 amino acids with a molecular weight of approximately 52,000 Da and 3 distinct domains;
- (c) contacting the cloned Gc1 protein with immobilized beta galactosidase and sialidase; and
- (d) obtaining the cloned macrophage activating factor (GcMAFc).

Claim 23 (Canceled)

24. (Currently Amended) A process for producing a functional cloned macrophage activating factor (GcMAFc) comprising:

- (a) cloning a Gc1 isoform into a baculovirus vector;
- ~~(b) sequencing the cloned Gc1 isoform, thereby confirming that the cloned Gc1 isoform is a wild type Gc1 isoform;~~
- ~~(e)(b)~~ expressing the ~~sequenced wild type~~ Gc1 isoform, thereby producing a cloned ~~wild type~~ Gc1 protein, wherein the cloned ~~wild type~~ Gc1 protein comprises approximately 458 amino acids with a molecular weight of approximately 52,000 Da and 3 distinct domains;
- (c) sequencing the cloned Gc1 peptide, thereby confirming that the cloned Gc1 protein is a cloned wild type Gc1 protein;
- (d) contacting the cloned wild type Gc1 protein in vitro with immobilized beta galactosidase and sialidase, and

Application No. 09/826,463

Reply to Office Action dated March 2, 2005

- (e) obtaining the cloned wild type macrophage activating factor (GcMAFc).